Menu

Experience

Natasha Leskovsek

    • Structure Therapeutics – $185.3 Million IPO 


    • Apollo Endosurgery to Be Acquired by Boston Scientific 


    • CinCor Pharma to Sell to AstraZeneca for Approximately $1.8 Billion 


    • Tmunity Therapeutics Agrees to Sell to Kite 


    • Horizon Therapeutics to Be Acquired by Amgen for Approximately $28 Billion 


    • ZitSticka sells to Heyday 


    • Oyster Point Pharma to Be Acquired by Viatris 


    • Tempus Labs – $175 Million in Funding 


    • Poseida Therapeutics Enters Strategic Collaboration and License Agreement With Roche 


    • Biotech Company ViaCyte to Be Acquired by Vertex Pharmaceuticals 


    • Cytokinetics – $450 Million Convertible Senior Notes Offering 


    • Sixth Street Invests in Blueprint Medicines 


    • Bristol Myers Squibb to Acquire Turning Point Therapeutics for $4.1 Billion 


    • Asymchem Agrees to Acquire Snapdragon Chemistry 


    • Arena Pharmaceuticals Agrees to Sell to Pfizer for $6.7 Billion 


    • Alvotech Agrees to Merge With SPAC Oaktree Acquisition Corp. II 


    • Baylis Medical Agrees to Sell to Boston Scientific for $1.75 Billion 


    • Flexion Therapeutics Agrees to Sell to Pacira BioSciences 


    • Warby Parker – Direct Listing 


    • ZOLL Medical Agrees to Acquire Itamar Medical for $538 Million 


    • Vividion Therapeutics Agrees to Sell to Bayer for up to $2 Billion 


    • Lyell Immunopharma – $425 Million IPO 


    • The Honest Company – $475 Million IPO 


    • Five Prime Therapeutics Agrees to Sell to Amgen for $1.9 Billion 


    • Horizon Therapeutics to Acquire Viela Bio 


    • Celularity to Go Public Through SPAC Merger 


    • Ovid - $75 Million IPO 


    • VelosBio Agrees to Sell to Merck for $2.75 Billion 


    • Genesis MedTech Acquires Drug Device Asset From TriReme Medical 


    • Forbius Agrees to Sell to Bristol Myers Squibb 


    • Neurocrine Partners With Takeda to Address Psychiatric Disorders 


    • Orca Bio Raises $192 Million Series D to Transform Allogenic Cell Therapy 


    • Avidity Biosciences - $289 Million IPO 


    • Vaxcyte - $288 Million IPO 


    • Fate Therapeutics Licensing and Platform Collaboration with Janssen Biotech 


    • Forty Seven Agrees to Sell to Gilead for $4.9 Billion  


    • Reata Pharmaceuticals – $505 Million Follow-On Offering 


    • argenx – $557 Million Follow-On Offering 


    • Synthorx to Sell to Sanofi for $2.5 Billion 


    • Avidity Biosciences – $100 Million Series C 


    • Innate Pharma - $79 Million IPO 


    • Vir Biotechnology - $143 Million IPO 


    • Bavarian Nordic Acquires Two Commercial Vaccines from GlaxoSmithKline for €796 Million 


    • Crown Bioscience Enters Merger Agreement With JSR Corporation 


    • Sucampo Sells to Mallinckrodt for $1.2 Billion 


    • Cell Design Labs Sells to Gilead 


    • ERYTECH – $144 Million IPO 


    • Cooley Advises on Nightstar + NuCana IPOs 


    • Zealand Pharma – $89 Million IPO 


    • Aridis – $26 Million IPO 


    • Horizon Pharma Buys River Vision for $145 Million and Unspecified Earn-Out 


    • SELLAS Life Sciences Group to Merge with Galena Biopharma 


    • ZELTIQ Aesthetics to Sell to Allergan for $2.5 Billion 


    • Medivation Agrees to Sell to Pfizer for $14 Billion 


    • Advaxis – $30 Million Registered Direct Offering 


    • Recro Pharma – $15 Million Follow-On  


    • Gemphire Therapeutics – $30 Million IPO 


    • Syros – $58 Million IPO 


    • Syros IPO – $58 Million 


    • Selecta Biosciences – $74 Million IPO 


    • Jazz Pharmaceuticals Acquires Celator for $1.5 Billion 


    • Oncobiologics – $40 Million IPO and Private Placement